We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

159 hedge funds and large institutions have $612M invested in Progenics Pharmaceuticals Inc in 2017 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 45 increasing their positions, 36 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 56 | Existing positions closed: 16

69% more call options, than puts

Call options by funds: $6.1M | Put options by funds: $3.62M

26% more funds holding

Funds holding: 126 → 159 (+33)

25% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 36

18% more capital invested

Capital invested by funds: $518M → $612M (+$93.5M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
159
Holders Change
+33
Holders Change %
+26.19%
% of All Funds
3.96%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
56
Increased
45
Reduced
36
Closed
16
Calls
$6.1M
Puts
$3.62M
Net Calls
+$2.48M
Net Calls Change
+$1.34M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$95M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$13M
3
PWAM
Park West Asset Management
California
+$12.6M
4
Invesco
Invesco
Georgia
+$10.3M
5
Goldman Sachs
Goldman Sachs
New York
+$5.62M

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$69.4M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$5.91M
3
AllianceBernstein
AllianceBernstein
Tennessee
-$2.13M
4
RA
Royce & Associates
New York
-$2.08M
5
PFC
Phocas Financial Corp
California
-$1.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
Ameriprise
26
Ameriprise
Minnesota
$3.47M +$3.67M +367,798 New
Charles Schwab
27
Charles Schwab
California
$3.23M +$671K +67,271 +24%
Acadian Asset Management
28
Acadian Asset Management
Massachusetts
$2.67M +$2.82M +282,701 New
Morgan Stanley
29
Morgan Stanley
New York
$2.59M -$1.03M -102,821 -27%
GC
30
Guggenheim Capital
Illinois
$2.58M +$2.72M +272,801 New
Millennium Management
31
Millennium Management
New York
$2.52M -$681K -68,211 -20%
Renaissance Technologies
32
Renaissance Technologies
New York
$2.3M +$2.43M +243,389 New
AllianceBernstein
33
AllianceBernstein
Tennessee
$2.27M -$2.13M -213,410 -47%
Wellington Management Group
34
Wellington Management Group
Massachusetts
$2.09M +$1.3M +130,046 +143%
New York State Common Retirement Fund
35
New York State Common Retirement Fund
New York
$2.04M +$67.6K +6,772 +3%
Allianz Asset Management
36
Allianz Asset Management
Germany
$1.96M -$31.7K -3,173 -2%
Russell Investments Group
37
Russell Investments Group
United Kingdom
$1.9M +$2.01M +201,066 New
TCIM
38
TIAA CREF Investment Management
New York
$1.81M -$109K -10,897 -5%
Wells Fargo
39
Wells Fargo
California
$1.76M -$136K -13,646 -7%
California Public Employees Retirement System
40
California Public Employees Retirement System
California
$1.63M -$74.9K -7,500 -4%
CS
41
Credit Suisse
Switzerland
$1.45M +$726K +72,706 +90%
CAM
42
ClariVest Asset Management
California
$1.37M +$1.45M +144,967 New
Susquehanna International Group
43
Susquehanna International Group
Pennsylvania
$1.29M -$603K -60,393 -31%
California State Teachers Retirement System (CalSTRS)
44
California State Teachers Retirement System (CalSTRS)
California
$1.29M -$63.9K -6,400 -4%
RhumbLine Advisers
45
RhumbLine Advisers
Massachusetts
$1.28M +$579K +58,042 +75%
Citadel Advisors
46
Citadel Advisors
Florida
$1.24M +$1.11M +111,547 +566%
Prudential Financial
47
Prudential Financial
New Jersey
$1.21M +$1.28M +127,972 New
TA
48
Teachers Advisors
New York
$1.14M +$85.3K +8,544 +8%
KBC Group
49
KBC Group
Belgium
$1.1M +$1.17M +116,904 New
Legal & General Group
50
Legal & General Group
United Kingdom
$1.1M +$991K +99,267 +577%
1
2
3 4 5

PGNX Hedge Fund Activity: Q1 2017 in Review

159 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q1 2017, worth a combined $612M — up 18% from $518M a quarter earlier.

Buyers outnumbered sellers: 56 funds opened new PGNX positions and 16 closed out — a net gain of 40 holders — while 45 added to existing stakes and 36 trimmed.

The largest buyer was BlackRock, adding an estimated $95M. The largest seller was Broadfin Capital, cutting an estimated $69.4M.

  • 159 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q1 2017, up from 126 in Q4 2016.
  • Funds reported $612M of Progenics Pharmaceuticals Inc stock for Q1 2017, up 18% quarter-over-quarter.
  • 56 funds opened new Progenics Pharmaceuticals Inc positions in Q1 2017 and 16 closed out, a net change of +40 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q1 2017 was BlackRock, an estimated $95M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q1 2017 was Broadfin Capital, an estimated $69.4M sold.

Based on aggregated 13F filings for Q1 2017.